Clinical trials: Nash
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver
This is a randomized, double-blinded, placebo-controlled clinical trial aimed at evaluating the efficacy and safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF) for non-alcoholic fatty liver.
- Trial name
- LJF (NCT07637006)
- Testing
- Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF)
- Volunteers
- 180 people
- Sponsor
- Hong Kong Baptist University
Nonalcoholic Steatohepatitis
Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers
Fasting Period: At least 10 hours prior to dosing until 4 hours post-dose of each study period. Period: 24 hours post dose in each period. Each subject will complete two study periods.
- Trial name
- NCT05983328
- Testing
- HUYPS-1 one tablet, HUYPS-1 nine tablets
- Where
- Taiwan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Mafld in Ckd Patients
Association Betweenq MAFLD ( Metabolic Associated Fatty Liver Disease) and Chronic Kidney Disease
Assess frequency of renal affection in mafld
- Trial name
- NCT06135467
- Volunteers
- 150 people
- Sponsor
- Assiut University
Metabolic Syndrome, Fatty Liver Disease
Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV
1. investigate the Prevalence of combined hepatic steatosis in patients with chronic HBV. 2. to evaluate clinical characteristics of chronic HBV patients combined with metabolic syndrome and hepatic steatosis
- Trial name
- NCT06589167
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Steatohepatitis (NASH), Type2 Diabetes Mellitus
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
This is an open, pilot study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM or pre-diabetes.
- Trial name
- NCT02653300
- Testing
- Oral Insulin
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Oramed, Ltd.
Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Conditions
- Metabolic Syndrome, Non Alcoholic Fatty Liver Disease, Insulin Resistance
- Trial name
- GC-NASH (NCT01553500)
- Testing
- glucomannan, lifestyle intervention
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Non Alcoholic Steatohepatitis
Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of hepatic pathology, ranging from simple steatosis, steatohepatitis, to cirrhosis.
- Trial name
- NCT01279434
- Testing
- Vitamin E plus Pentoxiphyllin, Vitamin E
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Obesity, Nonalcoholic Fatty Liver Disease
Fatty Liver Disease in Obese Children
Although weight reduction through physical activity-based interventions is the mainstay therapy for nonalcoholic fatty liver disease (NAFLD), its maintenance is difficult and typically unsuccessful.
- Conditions
- Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
- Trial name
- NCT02117700
- Testing
- N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nemours Children's Clinic
Non-Alcoholic Fatty Liver Disease, Liver Fat
Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
This study will assess the impact of 8-hour time restricted eating (8 hours of eating, 16 hours fasting) combined with a Mediterranean diet on metabolism and inflammation in adults with non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Fat, Obesity, Inflammation
- Trial name
- NCT05968378
- Testing
- Standard healthy eating advice, eTRE plus Mediterranean diet
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- University College Dublin
Nonalcoholic Fatty Liver Disease
Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout
Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China.
- Trial name
- NCT04772352
- Testing
- febuxostat treatment, lifestyle intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ningbo No. 1 Hospital
Non-Alcoholic Fatty Liver Disease, Osteoporosis
Effect of Fatty Liver Disease on Bone Density
Non Alcohlic Fatty Liver (NAFLD) is a spectrum of diseases that ranges from accumulation of fat in the liver (Hepatosteatosis) that may be accompanied by inflammation (Steatohepatitis) to necrosis, fibrosis and even cirrhosis…
- Trial name
- NCT04850547
- Volunteers
- 80 people
- Sponsor
- Sohag University
Obesity
Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy
Evaluation of the diagnostic performance of an algorithm developed to detect metabolic profiles specific of non-alcoholic steatohepatitis NASH and based on the reading of a blood sample's infrared spectra
- Trial name
- SIGNALS (NCT03978247)
- Testing
- NASHMIR
- Where
- Belgium
- Volunteers
- 382 people
- Sponsor
- Diafir
Fatty Liver Disease
Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on Fatty Liver
Objectives: To examine the effects of tablets of silybum marianum, Pueraria lobate and salvia miltiorrhiza on the progression of fatty liver in patients with fatty liver.
- Trial name
- NCT05076058
- Testing
- Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Sun Yat-sen University
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Trial name
- EU-PNAFLD (NCT04190849)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
NAFLD, Diabetes
GLP-1 RA on Liver OMICS in MASLD
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue.
- Conditions
- NAFLD, Diabetes, Obesity
- Trial name
- OMICS in MASLD (NCT06982378)
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
Non-alcoholic Fatty Liver Disease (NAFLD)
Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence.
A key element in the diagnosis of non-alcoholic fatty liver disease (NAFLD) is the differentiation of non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver (NAFL) and the staging of the liver fibrosis, given that…
- Trial name
- NASHAI (NCT04099147)
- Testing
- This is an observational study.
- Volunteers
- 14,046 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Hepatic Fat Accumulation, Nonalcoholic Fatty Liver Disease
Dietary Protein and Hepatic Fat Accumulation
The objective of this study is to investigate the potential beneficial effect of increasing protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet.
- Trial name
- LiF-Pro (NCT01354626)
- Testing
- dietary protein, low-protein
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Nonalcoholic Fatty Liver Disease
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is one of the most common chronic liver diseases worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of the disease which runs a progressive course and may result in liver cirrhosis…
- Trial name
- NCT01210989
- Testing
- Phyllanthus urinaria
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Non Alcoholic Steatohepatitis
Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis
120 patients of biopsy proven NASH will be randomized into two groups. Cases group will receive combination of pentoxiphylline and Vitamin E, and control group will receive only Vitamin E.
- Trial name
- NCT01384578
- Testing
- pentoxiphylline and Vitamin E, Vitamin E
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.